Page 7 - Eric Rojas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bolder Boulder names Ric Rojas, daughter Nell as official 2023 race starters

Bolder Boulder names Ric Rojas, daughter Nell as official 2023 race starters
timescall.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timescall.com Daily Mail and Mail on Sunday newspapers.

United statesNell rojasCliff bosleyBolder boulderEric rojasBoston marathonBoulder high

Michael Sandrock: Marc Hunter s legacy endures

Marc Hunter's 1980 win shows the paradox of racing the Bolder Boulder most efficiently and any long distance race going out slower can make you faster.

United statesBoulder high schoolSteve flotoJohn treacyMichael sandrockSteve jonesCliff bosleyFrank shorterLee troopSteve bosleyAlan culpepperJoan humphriesJoe bosshardSteve plascenciaHenry ronoColleen de reuck

Stoke Therapeutics : Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 - Form 8-K

- Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 - - Company plans to initiate a pivotal study. | May 4, 2023

United kingdomUnited statesEdwardm kayeEric rojasStoke therapeutics incExchange commissionAugmentation of nuclear gene outputRegulatory agencyStoke therapeutics inc nasdaqCompany annual report on formAugmentation of nuclear gene output is stokeAutosomal dominant optic atrophyChief executive officerRecent developmentsClinical trial applicationUnited kingdom medicines

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

– Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 –– Company plans to initiate.

United kingdomUnited statesEric rojasEdwardm kayeExchange commissionStoke therapeutics incAugmentation of nuclear gene output is stokeAugmentation of nuclear gene outputCompany annual report on formRegulatory agencyAutosomal dominant optic atrophyStoke therapeuticsChief executive officerClinical trial applicationUnited kingdom medicinesCollaboration agreement

Stoke Therapeutics, Inc : Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

- Company advancing second TANGO ASO into the clinic - - STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve

United kingdomUnited statesBarry tichoEric rojasCompany annual report on formAugmentation of nuclear gene outputRegulatory agencyAugmentation of nuclear gene output is stokeExchange commissionStoke therapeutics incClinical trial applicationUnited kingdom medicinesChief medical officerAutosomal dominant optic atrophyTargeted augmentationNuclear gene output